128 related articles for article (PubMed ID: 9713367)
1. The immunohistochemical detection of cripto-1 in benign and malignant human bladder.
Byrne RL; Autzen P; Birch P; Robinson MC; Gullick WJ; Neal DE; Hamdy FC
J Pathol; 1998 May; 185(1):108-11. PubMed ID: 9713367
[TBL] [Abstract][Full Text] [Related]
2. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
3. Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer.
Ow K; Delprado W; Fisher R; Barrett J; Yu Y; Jackson P; Russell PJ
J Pathol; 2000 May; 191(1):39-47. PubMed ID: 10767717
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer.
Cardillo MR; Castagna G; Memeo L; De Bernardinis E; Di Silverio F
J Exp Clin Cancer Res; 2000 Jun; 19(2):225-33. PubMed ID: 10965823
[TBL] [Abstract][Full Text] [Related]
6. Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder.
Tong GX; Yee H; Chiriboga L; Hernandez O; Waisman J
Hum Pathol; 2005 Jul; 36(7):741-6. PubMed ID: 16084942
[TBL] [Abstract][Full Text] [Related]
7. Expression of cathepsin D in transitional cell bladder tumours.
Lipponen PK
J Pathol; 1996 Jan; 178(1):59-64. PubMed ID: 8778318
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival.
Gong YP; Yarrow PM; Carmalt HL; Kwun SY; Kennedy CW; Lin BP; Xing PX; Gillett DJ
Eur J Surg Oncol; 2007 May; 33(4):438-43. PubMed ID: 17125961
[TBL] [Abstract][Full Text] [Related]
9. Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors.
Saeki T; Stromberg K; Qi CF; Gullick WJ; Tahara E; Normanno N; Ciardiello F; Kenney N; Johnson GR; Salomon DS
Cancer Res; 1992 Jun; 52(12):3467-73. PubMed ID: 1596904
[TBL] [Abstract][Full Text] [Related]
10. Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic urinary bladder.
Booth C; Harnden P; Selby PJ; Southgate J
J Pathol; 2002 Nov; 198(3):359-68. PubMed ID: 12375269
[TBL] [Abstract][Full Text] [Related]
11. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
12. Potential for molecular-targeted therapy targeting human epidermal growth factor receptor-2 for invasive bladder cancer.
Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Inoue Y; Noguchi H; Honda N
Oncol Rep; 2007 Jul; 18(1):3-7. PubMed ID: 17549338
[TBL] [Abstract][Full Text] [Related]
13. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
14. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
[TBL] [Abstract][Full Text] [Related]
15. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.
Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO
BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711
[TBL] [Abstract][Full Text] [Related]
16. CD40 expression in bladder cancer.
Cooke PW; James ND; Ganesan R; Wallace M; Burton A; Young LS
J Pathol; 1999 May; 188(1):38-43. PubMed ID: 10398138
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
18. Cripto-1 expression in uveal melanoma: an immunohistochemical study.
Mallikarjuna K; Vaijayanthi P; Krishnakumar S
Exp Eye Res; 2007 Jun; 84(6):1060-6. PubMed ID: 17412323
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.
Lipponen P; Aaltoma S; Kosma VM; Ala-Opas M; Eskelinen M
J Pathol; 1998 Oct; 186(2):157-64. PubMed ID: 9924431
[TBL] [Abstract][Full Text] [Related]
20. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
